This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Spine Radiosurgery for Symptomatic Metastatic Neoplasms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05617716
Recruitment Status : Recruiting
First Posted : November 15, 2022
Last Update Posted : October 4, 2023
Sponsor:
Information provided by (Responsible Party):
Case Comprehensive Cancer Center

Brief Summary:
The purpose of this study is to compare three types of radiation therapy for cancer that has spread to the spine. The two types of radiation therapy used in this trial are External Beam Radiation Therapy (EBRT) and Stereotactic Body Radiation Therapy (SBRT). EBRT delivers tightly targeted radiation beams from outside the body. SBRT is a specialized type of radiation therapy that allows high doses of radiation to small targets. This study will include standard dose SBRT and higher dose SBRT. Each participant will be randomly assigned to either EBRT, standard dose SBRT, or higher dose SBRT.

Condition or disease Intervention/treatment Phase
Metastatic Neoplasm to the Spine Metastatic Neoplasm Radiation: Conventional external beam radiation therapy dose (EBRT) Radiation: Spine radiosurgery/stereotactic body radiation therapy standard dose Radiation: Spine radiosurgery/stereotactic body radiation therapy high dose Phase 2

Detailed Description:
Metastatic spine cancer incidence is increasing; the primary treatment is radiation therapy. Metastatic spine disease has been historically treated with external beam radiation therapy (EBRT) with conventional fractionation, yielding relatively limited durability in pain control. The increased lifespan of patients with metastatic cancer has resulted in an increase in the incidence of spine metastases, which has led to a need for more durable treatment results. Stereotactic radiosurgery (SRS)/Stereotactic body radiation therapy (SBRT) of the spine has exponentially increased, with the theoretical advantages of higher tumoricidal dose and more rapid fall off between tumor and surrounding normal tissue compared with EBRT. The goal of this study is to compare three types of radiation therapy to draw conclusions on what is an effective treatment to reduce pain and increase pain freedom rates.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN) Multicenter Randomized Phase II Clinical Trial
Actual Study Start Date : January 25, 2023
Estimated Primary Completion Date : June 30, 2026
Estimated Study Completion Date : December 31, 2026

Arm Intervention/treatment
Experimental: Standard dose SBRT
Participants will undergo standard dose Stereotactic Body Radiation Therapy
Radiation: Spine radiosurgery/stereotactic body radiation therapy standard dose
Participants will undergo 24 Gray in 2 fractions of SBRT

Experimental: High dose SBRT
Participants will undergo high dose Stereotactic Body Radiation Therapy
Radiation: Spine radiosurgery/stereotactic body radiation therapy high dose
Participants will undergo 19 Gray in 1 fraction of SBRT

Experimental: Conventional EBRT
Participants will undergo External Beam Radiation Therapy
Radiation: Conventional external beam radiation therapy dose (EBRT)
Participants will undergo 8 Gray in 1 fraction of EBRT




Primary Outcome Measures :
  1. Pain freedom based on BPI score difference [ Time Frame: 3 months ]
    Freedom from pain at 3 months defined as pain freedom following spine SBRT/EBRT per the Brief Pain Inventory (BPI), which is a scale of 1-10. The complete response for pain freedom is defined as a "worst" pain score of 0 on the BPI. Partial pain freedom is defined as a "worst" pain score of 2 points on the BPI.


Secondary Outcome Measures :
  1. Pain freedom based on BPI score difference [ Time Frame: 6 months ]
    Freedom from pain at 6 months defined as pain freedom following spine SBRT/EBRT per the Brief Pain Inventory (BPI), which is a scale of 1-10. The complete response for pain freedom is defined as a "worst" pain score of 0 on the BPI. Partial pain freedom is defined as a "worst" pain score of 2 points on the BPI.

  2. Local Control [ Time Frame: 6 months ]
    6-month local control, defined as an actuarial 6-month rate of any new, recurrent or progressing (as defined by SPINOcriteria) tumor within the planning target volume on any post-treatment MRI by 6 months. Follow-up MRIs will be fused with the planning scan for this assessment

  3. Vertebral compression fracture rate [ Time Frame: 6 months ]
    6-month vertebral compression fracture rate, assessed by post-treatment MRI by 6 months

  4. Survival [ Time Frame: 6 months ]
    Overall participant survival

  5. Vertebral compression fracture rate [ Time Frame: 12 months ]
    12-month vertebral compression fracture rate, assessed by post-treatment MRI at 12 months

  6. Demographic disparities [ Time Frame: 3 months ]
    Demographic disparities (by race, ethnicity, gender identity, sexual orientation, insurance status) following spine SBRT/EBRT access and outcomes at 3 months

  7. Demographic disparities [ Time Frame: 6 months ]
    Demographic disparities (by race, ethnicity, gender identity, sexual orientation, insurance status) following spine SBRT/EBRT access and outcomes at 6 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant must have histologic confirmation of malignancy. Spinal metastatic disease must be confirmed by imaging.
  • Participant must have received no prior therapies for this disease. Prior therapy includes previous radiation therapy encompassing the anatomic site to be treated with spine SBRT. This includes any previous radiation therapy where the treatment field overlaps with the anatomic site to be treated with spine SBRT (even if that previous radiation therapy was not for treatment of spinal disease). Systemic radiation therapy for metastatic disease such as Pluvicto also counts as previous radiation therapy.
  • Age >18 years. This study requires informed consent by the participant; as children are not able to perform this without parental approval, Participant < age 18 are excluded from this study.
  • Life expectancy of≥ 3 months, in the opinion of and as documented by the investigator.
  • Participant must have a worst pain score < 2 of 10 according to the Brief Pain Inventory
  • Participant must have no intention of changing pain medications on the first day of SBRT
  • Participant must have a Spinal Instability score (SINS) ≤ 12
  • Participant must be a spine SBRT candidate per Radiation Oncology
  • Participant must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Participant receiving any other investigational agents.
  • Participant with prognosis less than 3 months will be excluded from this clinical trial because of their poor prognosis and decreased likelihood to meet the primary endpoint
  • Participant with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or nursing Participant are excluded due to toxicity of radiation therapy.
  • Participant is unable to receive MRI of the spine
  • Participant has a Spinal Instability in Neoplasia score (SINS) ≥ 12
  • Participant has received previous stereotactic radiosurgery where the 50% isodose line overlaps with current treatment field
  • Participant has more than 3 consecutive vertebral bodies in the SBRT treatment volume
  • Participant is not an SBRT candidate per radiation oncology discretion
  • Participant has a known primary and has an estimated median survival≤ 3 months
  • Participant has an unknown primary
  • Participant has a Brief Pain Inventory score > 2
  • Participant has received previous radiation therapy involving the intended SBRT treatment field
  • Participant has received previous spinal surgical procedure involving the SBRT target volume. Biopsy is not considered a previous spinal surgical procedure.
  • Participant has neurological deficits from malignant cauda equina compression or epidural spinal cord compression

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05617716


Contacts
Layout table for location contacts
Contact: Shearwood McClelland III, MD 1-800-641-2422 CTUReferral@UHhospitals.org

Locations
Layout table for location information
United States, Ohio
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Shearwood McClelland, MD    800-641-2422    CTUReferral@UHhospitals.org   
Sponsors and Collaborators
Case Comprehensive Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Shearwood McClelland III, MD University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT05617716    
Other Study ID Numbers: CASE4322
First Posted: November 15, 2022    Key Record Dates
Last Update Posted: October 4, 2023
Last Verified: October 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD sharing includes individual participant data that underlie or influence the results observed in this study.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Beginning 3 months and ending 5 years following article publication
Access Criteria: Investigators who provide a methodologically sound proposal for use of requested data

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Case Comprehensive Cancer Center:
Radiosurgery
External Beam Radiation Therapy
Stereotactic Body Radiation Therapy
Spine Stereotactic Radiosurgery
SPORTSMEN
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Neoplastic Processes
Pathologic Processes